---
title: "Bank of America Securities Remains a Buy on Teva Pharmaceutical (TEVA)"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/269071586.md"
description: "Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Teva Pharmaceutical with a $32.00 price target. Teva's shares closed at $28.33, and the analyst consensus is Strong Buy with a $31.22 price target. Barclays also initiated coverage with a Buy rating and a $35.00 price target."
datetime: "2025-12-09T10:35:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/269071586.md)
  - [en](https://longbridge.com/en/news/269071586.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/269071586.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/269071586.md) | [English](https://longbridge.com/en/news/269071586.md)


# Bank of America Securities Remains a Buy on Teva Pharmaceutical (TEVA)

In a report released yesterday, Jason Gerberry from Bank of America Securities reiterated a Buy rating on Teva Pharmaceutical, with a price target of $32.00. The company’s shares closed yesterday at $28.33.

### TipRanks Cyber Monday Sale

-   Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
-   Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off

Gerberry covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, and Jazz Pharmaceuticals. According to TipRanks, Gerberry has an average return of 15.0% and a 60.49% success rate on recommended stocks.

Teva Pharmaceutical has an analyst consensus of Strong Buy, with a price target consensus of $31.22, which is a 10.20% upside from current levels. In a report released yesterday, Barclays also initiated coverage with a Buy rating on the stock with a $35.00 price target.

### 相關股票

- [Teva Pharmaceutical Industries (TEVA.US)](https://longbridge.com/zh-HK/quote/TEVA.US.md)

## 相關資訊與研究

- [Missile Strike Tests Teva Supply Resilience And Biosimilar Growth Plans](https://longbridge.com/zh-HK/news/281381492.md)
- [Teva Pharmaceutical Gets US FDA Approval for Prolia Biosimilar; Xoliar Biosimiliar Applications Accepted in US, Europe](https://longbridge.com/zh-HK/news/281026919.md)
- [Teva Pharmaceutical Industries Ltd Announces Fda Approval of Ponlimsi and Dual Filing Acceptance for Biosimilar Candidate to Xolair](https://longbridge.com/zh-HK/news/281041875.md)
- [Guoyuan Securities (HK) Keeps Their Buy Rating on Nongfu Spring Co., Ltd. Class H (9633)](https://longbridge.com/zh-HK/news/281480401.md)
- [Zephirin Adjusts Meituan's Price Target to HK$56 from HK$54, Keeps at Sell](https://longbridge.com/zh-HK/news/280991144.md)